Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11760763 Heteroaryl compounds useful as MK2 inhibitors

Patent 11760763 was granted and assigned to Bristol-Myers Squibb on September, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Current Assignee
Bristol-Myers Squibb
Bristol-Myers Squibb
Date Filed
September 17, 2021
Date of Patent
September 19, 2023
Patent Application Number
17477649
Patent Citations
‌
US Patent 9790235 MK2 inhibitors and uses thereof
‌
US Patent 10138256 MK2 inhibitors and uses thereof
‌
US Patent 10253040 MK2 inhibitors and uses thereof
‌
US Patent 10577380 MK2 inhibitors and uses thereof
‌
US Patent 10894796 MK2 inhibitors, synthesis thereof, and intermediates thereto
‌
US Patent 10882867 Forms and compositions of a MK2 inhibitor
‌
US Patent 11230551 Deuterated analogs of MK2 inhibitors and uses thereof
‌
US Patent 7517990 Method for deuteration of a heterocyclic ring
‌
US Patent 7838674 Tetracyclic lactame derivatives
‌
US Patent 9458175 MK2 inhibitors and uses thereof
Patent Inventor Names
Jian Guo
John Malona
Sekhar S. Surapaneni
Alexander L. Ruchelman
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11760763
Patent Primary Examiner
‌
Bruck Kifle
CPC Code
‌
A61K 31/551
‌
C07D 495/14

Find more entities like US Patent 11760763 Heteroaryl compounds useful as MK2 inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo